156 related articles for article (PubMed ID: 15020271)
1. Splenectomy in relapsing and plasma-refractory acquired thrombotic thrombocytopenic purpura.
Kremer Hovinga JA; Studt JD; Demarmels Biasiutti F; Solenthaler M; Alberio L; Zwicky C; Fontana S; Taleghani BM; Tobler A; Lämmle B
Haematologica; 2004 Mar; 89(3):320-4. PubMed ID: 15020271
[TBL] [Abstract][Full Text] [Related]
2. The course of ADAMTS-13 activity and inhibitor titre in the treatment of thrombotic thrombocytopenic purpura with plasma exchange and vincristine.
Böhm M; Betz C; Miesbach W; Krause M; von Auer C; Geiger H; Scharrer I
Br J Haematol; 2005 Jun; 129(5):644-52. PubMed ID: 15916687
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for treatment of refractory/relapsing thrombotic thrombocytopenic purpura (TTP).
Ahmad A; Aggarwal A; Sharma D; Dave HP; Kinsella V; Rick ME; Schechter GP
Am J Hematol; 2004 Oct; 77(2):171-6. PubMed ID: 15389904
[TBL] [Abstract][Full Text] [Related]
4. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP).
Kremer Hovinga JA; Studt JD; Lämmle B
Pathophysiol Haemost Thromb; 2003 Sep-2004 Dec; 33(5-6):417-21. PubMed ID: 15692254
[TBL] [Abstract][Full Text] [Related]
5. Prolonged inhibition of von Willebrand factor-cleaving protease after splenectomy in a 22-year-old patient with acute and plasma refractory thrombotic thrombocytopenic purpura.
Langer F; Bergmann F; Budde U; Hegewisch-Becker S; Hossfeld DK
Br J Haematol; 2002 Jul; 118(1):271-4. PubMed ID: 12100160
[TBL] [Abstract][Full Text] [Related]
6. Aetiology and pathogenesis of thrombotic thrombocytopenic purpura and haemolytic uraemic syndrome: the role of von Willebrand factor-cleaving protease.
Furlan M; Lämmle B
Best Pract Res Clin Haematol; 2001 Jun; 14(2):437-54. PubMed ID: 11686108
[TBL] [Abstract][Full Text] [Related]
7. Plasma therapy in thrombotic thrombocytopenic purpura: review of the literature and the Bern experience in a subgroup of patients with severe acquired ADAMTS-13 deficiency.
Fontana S; Kremer Hovinga JA; Studt JD; Alberio L; Lämmle B; Taleghani BM
Semin Hematol; 2004 Jan; 41(1):48-59. PubMed ID: 14727259
[TBL] [Abstract][Full Text] [Related]
8. Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura.
Furlan M; Robles R; Morselli B; Sandoz P; Lämmle B
Thromb Haemost; 1999 Jan; 81(1):8-13. PubMed ID: 10348715
[TBL] [Abstract][Full Text] [Related]
9. Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura.
Aqui NA; Stein SH; Konkle BA; Abrams CS; Strobl FJ
J Clin Apher; 2003; 18(2):51-4. PubMed ID: 12874815
[TBL] [Abstract][Full Text] [Related]
10. Clinical usefulness of a functional assay for the von Willebrand factor cleaving protease (ADAMTS 13) and its inhibitor in a patient with thrombotic thrombocytopenic purpura.
Rick ME; Austin H; Leitman SF; Krizek DM; Aronson DL
Am J Hematol; 2004 Feb; 75(2):96-100. PubMed ID: 14755376
[TBL] [Abstract][Full Text] [Related]
11. Nonneutralizing IgM and IgG antibodies to von Willebrand factor-cleaving protease (ADAMTS-13) in a patient with thrombotic thrombocytopenic purpura.
Scheiflinger F; Knöbl P; Trattner B; Plaimauer B; Mohr G; Dockal M; Dorner F; Rieger M
Blood; 2003 Nov; 102(9):3241-3. PubMed ID: 12855569
[TBL] [Abstract][Full Text] [Related]
12. Effect of splenectomy on von Willebrand factor multimeric structure in thrombotic thrombocytopenic purpura refractory to plasma exchange.
Pereira A; Monteagudo J; Bono A; Lopez-Guillermo A; Ordinas A
Blood Coagul Fibrinolysis; 1993 Oct; 4(5):783-6. PubMed ID: 8292728
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in thrombotic thrombocytopenic purpura.
Sadler JE; Moake JL; Miyata T; George JN
Hematology Am Soc Hematol Educ Program; 2004; ():407-23. PubMed ID: 15561695
[TBL] [Abstract][Full Text] [Related]
14. Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.
Tsai HM; Lian EC
N Engl J Med; 1998 Nov; 339(22):1585-94. PubMed ID: 9828246
[TBL] [Abstract][Full Text] [Related]
15. von Willebrand factor cleaving protease (ADAMTS-13) and ADAMTS-13 neutralizing autoantibodies in 100 patients with thrombotic thrombocytopenic purpura.
Peyvandi F; Ferrari S; Lavoretano S; Canciani MT; Mannucci PM
Br J Haematol; 2004 Nov; 127(4):433-9. PubMed ID: 15521921
[TBL] [Abstract][Full Text] [Related]
16. Schistocytic anaemia, severe thrombocytopenia, and renal dysfunction: thrombotic microangiopathy due to severe acquired ADAMTS-13 deficiency. Case 2.
Winkler A; Kremer Hovinga JA; Bianchi V; Studt JD; Lämmle B
Hamostaseologie; 2003 Aug; 23(3):103-8. PubMed ID: 12923577
[TBL] [Abstract][Full Text] [Related]
17. [Activity loss of Von Willebrand factor cleaving protein (ADAMTS-13) is diagnostic for primary and pregnancy-related thrombotic thrombocytopenic purpura].
Hulstein JJ; Rison CN; Kappers-Klunne MC; Hene RJ; Franx A; de Groot PG; Brand A; Fijnheer R
Ned Tijdschr Geneeskd; 2004 Oct; 148(40):1972-6. PubMed ID: 15524133
[TBL] [Abstract][Full Text] [Related]
18. Deficient activity of von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura.
Furlan M
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):243-55. PubMed ID: 15030284
[TBL] [Abstract][Full Text] [Related]
19. Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13.
Scully M; Cohen H; Cavenagh J; Benjamin S; Starke R; Killick S; Mackie I; Machin SJ
Br J Haematol; 2007 Feb; 136(3):451-61. PubMed ID: 17233847
[TBL] [Abstract][Full Text] [Related]
20. Management of thrombotic thrombocytopenic purpura.
Coppo P;
Transfus Clin Biol; 2017 Sep; 24(3):148-153. PubMed ID: 28645643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
